Company intelligence / Profile preview

Innate Biotherapeutics

New Zealand/Australia (historically headquartered in Auckland and Sydney)innatebio.com ↗

Ownership: Private
Development stage: Preclinical

Overview

The company's main technology was an engineered carbohydrate derived from fungi designed to stimulate the body's innate immune response. Clinical progress or results are not clearly documented in recent sources. There are no clear reports of late-stage clinical trials or commercial products. Company activity appears limited or paused as of latest available data.

Therapeutic areas: ImmunologyInfectious Diseases
Modalities: Engineered carbohydrates/complex polysaccharides that stimulate innate immunity[5]
Industry: Biotech

Beyond the preview

Go deeper on Innate Biotherapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Innate Biotherapeutics.

Explore the full profile